Company: ARWR
Filing Date: 2025-04-15
Form Type: 8-K
Source: 0001628280-25-017844
Chunk: 1

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-04-15
Form: 8-K
Item: Item 5.02
Chunk 1
---
 Trustee for the Health Institute of New Jersey. He earned a master's degree in Business Administration from the University of California, Berkeley, a bachelors of arts Degree from the University of Pennsylvania, and is a licensed Certified Public Accountant.

In connection with Mr. Apel’s appointment as Chief Financial Officer, Mr. Apel will receive an annual base salary of $575,00 and is eligible to receive an annual bonus with a target bonus set at 45% of his base salary for the applicable bonus period. In addition, Mr. Apel will receive a one-time grant of 100,000 restricted stock units (“ RSUs”), which will vest annually over a four-year period, subject to Mr. Apel’s continued service to the Company on each vesting date. The Company may also provide $200,000 in Company-paid relocation benefits to Mr. Apel.

There are no arrangements or understandings between Mr. Apel and any other persons pursuant to which Mr. Apel was selected as Chief Financial Officer of the Company. There are no family relationships between Mr. Apel and any director or executive officer of the Company, and Mr. Apel has no direct or indirect material interest in any transaction required to be disclosed pursuant toItem 404(a) of Regulation S-K nor are any such transactions currently proposed.

A copy of the press release is attached as Exhibit 99.1 and incorporated by reference into this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

  Exhibit No.      Description                                                                  
 ────────────────────────────────────────────────────────────────────────────────────────────────
         99.1      Press Release                                                                
          104      Cover Page Interactive Data File (embedded within the Inline XBRL document)  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: April 15 2025

  ARROWHEAD PHARMACEUTICALS, INC.                               
  By:                                  /s/ Kenneth Myszkowski   
                                       Kenneth Myszkowski       
                                       Chief Financial Officer